A 74-year-old woman with stage 3b chronic kidney disease and osteoporosis presents with BP 138/82 mmHg, HR 78/min, afebrile. She was previously on alendronate but experiences persistent GI intolerance. She is now switched to a subcutaneous monoclonal antibody that inhibits osteoclast activation by neutralizing RANK ligand. Recent bone density scan shows T-score of −2.8. Laboratory studies reveal normal serum calcium and phosphate. Which drug was most likely prescribed?
- A)Raloxifene
- B)Alendronate
- C)DenosumabGABARITO
- D)Teriparatide
- E)Calcitonin
Explicação
Denosumab is a monoclonal antibody against RANKL, so it suppresses osteoclast differentiation and activity. That antiresorptive mechanism makes it useful in osteoporosis, though hypocalcemia and osteonecrosis of the jaw are important adverse effects. Ver explicação completa e trilha adaptativa →